Article
Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.
Journal of the American Chemical Society - 27 Aug 2014
Ragland Debra A, Nalivaika Ellen A, Nalam Madhavi N L, Prachanronarong Kristina L, Cao Hong, Bandaranayake Rajintha M, Cai Yufeng, Kurt-Yilmaz Nese, Schiffer Celia A
Abstract excerpt
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in the treatment of HIV infection and AIDS. Darunavir (DRV) is the most potent of these inhibitors, soliciting drug resistance only when a complex combination of mutations occur both inside and outside the protease active site. With few exceptions, the role of mutations outside the active site in conferring resistance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.